CD274 and neoplasm: Additionally, PD-L1 expression, Epstein-Barr virus (EBV) infection, and circulating tumor DNA (ctDNA) are also biomarkers associated with the treatment outcomes of GC (136), with further clinical trials anticipated to validate their relevance.